NCT02692313

Dose Response of Epinephrine

Name: Clinical Trial NCT02692313
Creator: University of Maryland, Baltimore
Keywords: Diabetes Complications, Epinephrine, Early Phase 1, drug, clinical trial, United States of America

Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine

University of Maryland, Baltimore·Early Phase 1·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Diabetes Complications
Drug/Device/Intervention: Epinephrine
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: University of Maryland, Baltimore
Location: Baltimore, United States of America

Timeline & enrollment

Phase: Early Phase 1
Start date: Jun 01, 2016
End date: Feb 01, 2024
Enrollment: 32 participants

Primary outcome

Flow mediated dilation (FMD) of the brachial artery

Summary

Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. The specific aim of our study will be to determine the dose response effects of the key ANS counterregulatory hormone epinephrine on endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans.

ICD-10 classifications

Unspecified diabetes mellitus without complicationsOther specified diabetes mellitus with other specified complicationsOther specified diabetes mellitus without complicationsUnspecified diabetes mellitus with other specified complicationsOther specified diabetes mellitus with unspecified complications

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT02692313
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT02692313 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by University of Maryland, Baltimore and is currently Recruiting. The study focuses on Diabetes Complications. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.